Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.
about
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesFriend or foe: high bone mineral density on routine bone density scanning, a review of causes and managementA randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral densityAssociation between sclerostin and bone density in chronic spinal cord injuryLipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.Circulating sclerostin is elevated in short-term and reduced in long-term SCI.Secreted and transmembrane wnt inhibitors and activators.Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Sclerostin: therapeutic horizons based upon its actions.Sclerostin monoclonal antibodies on bone metabolism and fracture healing.The therapeutic potential of anti-interleukin-20 monoclonal antibody.N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats.IL-20 bone diseases involvement and therapeutic target potential.
P2860
Q26744599-A395AB42-D30F-4BB9-A55B-692BFFC91A77Q27025982-B00E73D7-F0E7-4336-B643-3D90CBBAE974Q28247445-EA167D5A-F885-426B-BD2E-4A1D7819C87CQ35782783-B431C688-04AD-4176-AC51-928B5B966B0AQ36117524-CB0F5818-B85C-424A-A181-17DE93AA393AQ36143807-11E75D8D-C054-48F1-B23C-ADBD6172272DQ36626700-2DAB954A-050A-4774-ADA6-6E525B0C6996Q36796273-AADA7F5E-FF0A-4EF6-B03D-0193BF5BB635Q37187646-C3AD1D0D-EAE1-450F-BFFA-1E18139F2C20Q37974871-9C901128-F2EB-4AE7-B8DF-FA0B8D5FBF4AQ38030984-E9559E2C-7251-4D27-BFB8-AAB0EF3E8E4DQ38210876-226AA9A1-1898-486B-B241-D2CB56E511FDQ39305265-75A6C20A-B8D5-40CA-86BF-FA849B9FE951Q50927799-78FC2F25-F021-4E9C-B58D-7465D115E17FQ53088327-744C6E0B-1965-4967-AEAD-48B20F4EADC3Q55121772-3483DCEF-6538-4F8E-B762-C876C9370A7D
P2860
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@en
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@nl
type
label
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@en
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@nl
prefLabel
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@en
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@nl
P2860
P1476
Sclerostin monoclonal antibody ...... al treatment for osteoporosis.
@en
P2093
E Michael Lewiecki
P2860
P304
P356
10.1517/14712598.2011.540565
P407
P577
2010-11-29T00:00:00Z